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Background: HIV-1 budding is directed primarily by two motifs in Gag p6 designated as late domain-1 and −2 that
recruit ESCRT machinery by binding Tsg101 and Alix, respectively, and by poorly characterized determinants in the
capsid (CA) domain. Here, we report that a conserved Gag p6 residue, S40, impacts budding mediated by all of
these determinants.
Results: Whereas budding normally results in formation of single spherical particles ~100 nm in diameter and
containing a characteristic electron-dense conical core, the substitution of Phe for S40, a change that does not alter
the amino acids encoded in the overlapping pol reading frame, resulted in defective CA-SP1 cleavage, formation of
strings of tethered particles or filopodia-like membrane protrusions containing Gag, and diminished infectious
particle formation. The S40F-mediated release defects were exacerbated when the viral-encoded protease (PR) was
inactivated or when L domain-1 function was disrupted or when budding was almost completely obliterated by
the disruption of both L domain-1 and −2. S40F mutation also resulted in stronger Gag-Alix interaction, as detected
by yeast 2-hybrid assay. Reducing Alix binding by mutational disruption of contact residues restored single particle
release, implicating the perturbed Gag-Alix interaction in the aberrant budding events. Interestingly, introduction of
S40F partially rescued the negative effects on budding of CA NTD mutations EE75,76AA and P99A, which both
prevent membrane curvature and therefore block budding at an early stage.
Conclusions: The results indicate that the S40 residue is a novel determinant of HIV-1 egress that is most likely
involved in regulation of a critical assembly event required for budding in the Tsg101-, Alix-, Nedd4- and
CA N-terminal domain affected pathways.
Keywords: HIV-1, Alix, Tsg101, Nedd4, CA NTD, Viral particle maturation, Protease, Viral buddingBackground
Gag, the structural precursor polyprotein encoded by all
retroviruses, is necessary and sufficient for assembly of
the immature viral particle [1]. Within the Gag polypro-
tein, the p6 region harbors important determinants of
viral budding (reviewed in [2-4]). A now apparent aspect
of Human Immunodeficiency Virus type 1 (HIV-1) repli-
cation is the existence of multiple independent pathways
for exit of progeny virus particles from the host cell. These* Correspondence: carol.carter@stonybrook.edu
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reproduction in any medium, provided the orpathways involve direct interaction between members
of or adapters of cellular ESCRT complexes and budding
determinants in the virus encoded structural precursor
polyprotein, Gag. Typically, budding of wild-type (WT)
Gag virus-like particles (VLPs) or of authentic virus
particles requires the binding of Tsg101, a component of
ESCRT-I, to the P7TAP motif in the C-terminal p6 region
of Gag (ESCRT = endosomal sorting complex required
for transport; ([5-7]; reviewed in [8-10]). The motif is des-
ignated as Late (L) domain-1. When Tsg101-PTAP inter-
action is disrupted, e.g., in the Gag mutant (P7L) where Leu
has been substituted for Pro7, budding becomes dependent
on L domain-2 in p6 (LY36PX2S40L; where X are highly,ral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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second budding pathway requires Alix interaction with
Gag through both p6 and determinants in nucleocapsid
(NC) [14]. Alix is an ESCRT adapter protein which,
upon oligomerization, links Gag to CHMP4 subunits in
ESCRT-III. Alix-mediated egress also requires Nedd4 [15].
In the absence of a functional L domain-1 and −2, viral
particles can still continue to use the cellular machinery
to bud through the plasma membrane through an E3
ubiquitin ligase-dependent pathway. A Nedd4 isoform,
Nedd4-2s (Nedd4L-ΔC2) can promote virus release when
L domain-1 is disrupted, whether or not L domain-2 is
intact [16,17]. The Nedd4 family of E3 ubiquitin ligases
bind to PPXY (designated as PY) motifs in several of the
retroviral Gag proteins and ubiquitinate these proteins
[18-20]. Interestingly, although HIV-1 Gag does not have
a PY motif, (i), it is known to be Ub-modified [21,22]; (ii),
viral budding is impacted by translational fusion of Ub
to Gag [23-26]; (iii), viral budding and infectivity have
been shown to be affected by changes in the levels of free
cellular Ub [23]; and (iv), Tsg101 has been reported to asso-
ciate with Nedd4 [16,27]. Thus, it is likely that Nedd4 plays
a role in HIV-1 egress.
L domain-1 is intact in all HIV-1 variants isolated to date
(Los Alamos National Laboratory (LANL) HIV database).
For this reason, L domain-2 is thought to have a secondary
redundant function versus L domain-1. Particularly intri-
guing is the high conservation of residue 40 in L Domain-
2 given that, based on structural studies [28-31], it is not a
residue that contacts Alix. Since p6 in the gag-ORF overlaps
with the transframe region (p6*) in the pol-ORF, residue
40 is Ser (S) in the context of the Gag precursor and
Phe (F) in the context of the Gag-Pol precursor where it
occupies the P1 position of the p6*/PR cleavage site.
Notwithstanding, it was recently reported that the
substitution of F for S at residue 40, a mutation that
does not alter the sequence of the overlapping pol
frame where the viral PR is encoded, results in a loss of
infectivity due to inefficient cleavage at the capsid-
spacer p1 (CA-SP1) junction [32]. Cleavage at this site
in the Gag precursor is required for the morphogenetic
rearrangements that produce the infectious particle
([33,34]; reviewed in [35-37]). This observation led the
authors to conclude that the p6 region may function in
viral maturation independently of its role in L domain-
mediated release.
In this report, we confirm that the S40F mutation
results in defects in particle maturation. Furthermore,
we show that the mutation altered the budding mediated
by determinants in both the p6 and the CA domains of
Gag. These studies suggest that the S40 residue in p6 is
an important determinant of a viral particle release step
that regulates an event common to the many budding
pathways used by the virus.Results
Mutation of S40 to Phe (S40F), which does not alter the
amino acid sequence in the overlapping pol reading
frame, nevertheless inhibits CA maturation, alters
budding, and reduces viral infectivity
To confirm the previously observed processing defect of
S40F, we engineered the mutation into pNL4-3-ΔEnv
and examined Gag processing products by Western
analysis. The pNL4-3ΔEnv construct encodes an active
PR and is capable of producing mature, noninfectious
particles [38]. Consistent with a previous finding [32], we
observed that S40F interfered with CA-SP1 to CA process-
ing, mature particle formation, and viral infectivity when
engineered into the pNL4-3 background. As expected,
in the VLPs detected in the media of COS-1 cells trans-
fected with pNL4-3ΔEnv-WT, proteolytic processing
generated almost exclusively the mature CA p24 protein
(Figure 1, panel A, lane 1). In contrast to WT and consist-
ent with the results of the previous study [32], the particles
released from cells transfected with S40F contained signifi-
cant levels of CA-SP1 (p25), indicating that processing at
the CA-SP1 junction was defective (panel A, lane 3).
The levels of accumulation of Gag and Gag-related prod-
ucts inside the cells appeared comparable although the pro-
cessing of CA-SP1 to CA was consistently reduced in cells
expressing the S40F mutation (compare lanes 1 and 3).
Unexpectedly, the mutation of S40 to A, a change that
alters the amino acid sequence at the p6*-PR cleavage site in
the overlapping pol frame, resulted in WT levels of CA-SP1
to CA processing, as assessed by Western blotting: VLPs
released from cells expressing S40A exhibited no defect in
CA-SP1 to CA processing (Figure 1, panel A, lane 2).
Thus, the impact of S40F is surprising. The current study
focuses on S40F.
S40F did not significantly affect the apparent viral
budding efficiency [CA-related signal intensity in VLP/
(VLP + cell lysate)], as judged by Western analysis (Figure 1,
panel A3). However, S40F produced a higher percentage of
immature or aberrant mature particles, as indicated by
electron microscopy (panel B). As shown in panel C
pNL4-3ΔEnv-WT produced three types of particles: (i)
immature VLPs, which have no internal core; (ii) VLPs
with aberrant internal core structures; and, predominantly,
(iii) VLPs that exhibited the cone-shaped internal core
structure characteristic of the mature, infectious WT virus
(solid arrow in panel B, left). The same three types of parti-
cles were found when cells were transfected with pNL4-
3ΔEnvS40F (panel B, right) except that the S40F mutant
produced significantly fewer particles with conical cores
and relatively more immature VLPs (open arrow) and
VLPs with aberrant cores (gray arrow). Approximately
50%, and 13% of the particles produced by pNL4-3
ΔEnv-WT, and -S40F, respectively, possessed mature
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Figure 1 Mutation of S40 to Phe, which does not alter the amino acid sequence in the overlapping pol reading frame, nevertheless
inhibits CA maturation, alters budding, and reduces viral infectivity. Panels A1-A3, Western blot analysis of pNL4-3ΔEnv WT, S40A and S40F
constructs which encode active protease. VLPs and cell lysates from COS-1 cells transfected with pNL4-3ΔEnv-WT (lane 1), pNL4-3ΔEnv-S40A
(lane 2) or pNL4-3ΔEnv-S40F (lane 3) were analyzed by Western blotting. The values in the figure indicate the ratio of p25/p24 normalized to wild
type. The relative VLP efficiencies [VLP/(VLP + Gag from cell lysate)] were determined as described in Methods. Panel B, Electron microscopy of
particles associated with cells transfected with pNL4-3ΔEnv-WT (panel B1), or S40F (panel B2). Immature particles (open arrows), particles with
aberrant cores (gray arrows), and mature particles with conical cones (solid arrows) were released from pNL4-3ΔEnv-transfected cells. Panel C,
Quantitative analysis. 25 WT or 100 S40F VLPs (n =2) were counted and the frequency of each type of particle was determined. Panel D, Viral
particle infectivity, determined by MAGI assay, done in triplicate.
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WT and are consistent with the observation that the
S40F mutant was more defective than the WT in CA
maturation. To evaluate viral particle infectivity, cells
were co-transfected with plasmids pNL4-3ΔEnv-WT, or
-S40F and pIIIB-Env-3-1 and the specific infectivity per
ng p24 in the cleared cell media was determined in
single-round assays using MAGI cells [39]. In agree-
ment with a previous study [32], the substitution of F
for S40 reduced viral infectivity 8- to 10- fold compared
to particles produced by the WT (panel D), (n = 6). The
results indicate that the S40F mutation impairs CA-SP1
processing, production of mature particles with conical
cores, and, thereby formation of infectious virus withoutaffecting the viral-encoded PR. S40F is therefore impacting
a Gag-related assembly function.
The defect resulting from S40F mutation becomes more
apparent when PR is inactive
Compared to WT, the VLPs made by pΔEnv-S40F appeared
to remain more cell-associated (c.f., panel B). This subtle
change, in addition to the observation that they were pre-
dominantly immature in morphology despite the presence
of mature p24, suggested that they had not been fully re-
leased from the cell and were thereby blocked at the CA
maturation cleavage which is a very late event. To deter-
mine whether the mutation affected viral assembly prior to
Gag processing, we used thin section electron microscopy
Watanabe et al. Retrovirology 2013, 10:143 Page 4 of 14
http://www.retrovirology.com/content/10/1/143to examine the particles produced by pHIV-1-gag-HA in
which the PR is absent. It is well-established that, all by
itself, WT Gag is sufficient for assembly and release of
immature VLPs [1]; (Figure 2, panels A and B). Immature
particles were also detected in the culture transfected with
DNA encoding S40F-Gag. However, in contrast to the single
spherical VLPs which the WT produced almost exclu-
sively, we observed that the majority of particles pro-
duced by S40F consisted either of spherical structures
that remained tethered to each other in short chains or
long (0.5 to 1.0 μm) membrane extensions that resembled
filopodia (panels C and D). The relative frequency of
particles by morphology is summarized in panel E.
Disrupting L domain-1 increases the effect of the S40F
mutation on budding
To determine whether the S40F mutation affected viral as-
sembly prior to particle budding, the L domain-1 (P7TAP)
was mutated to inhibit virus release. Cells were transfected
with P7L-Gag or P7L-S40F-Gag in which the P7L mutation
eliminates Tsg101 binding and results in inefficient bud
scission. As can be seen in Figure 3, the cells transfected
with P7L-S40F-Gag exhibited few of the typical virus-like
particles and instead were associated with elongated parti-
cles and filopodia-like structures (Figure 3, panel B). In
contrast, as expected, the surface of cells transfected with
the parental P7L-Gag accumulated single bud evaginations
and tethered lollipop-like structures (panel A). To confirm
that Gag was associated with the membrane extensions,
we examined the structures by immunoelectron micros-
copy. Cells were transfected, thin-sectioned for electron
microscopy, and then labeled with primary rabbit anti-CA
antibody that was tagged with 15 nm gold-conjugated
mouse anti-rabbit secondary antibody. The VLPs produced
by P7L-Gag were labeled with the gold-tagged antibody
probe (panel A2), as expected. In addition, cells in cultures
transfected with P7L-S40F possessed membrane extensions
labeled with the gold-tagged probe (panel B2) indicating
that Gag was associated. In some cases, the extensions con-
tacted neighboring cells, which is reminiscent of structures
reported for HIV-infected dendritic cells where viral egress
is coupled to virus-induced filopodia formation [40] A
quantitative analysis (panel C) in which ~200 gold-tagged
structures were examined in each culture indicated that the
P7L-S40F mutant produced the filopodia-like structures
to a significantly greater extent than the P7L parent.
VLP release efficiency was not affected for the P7L-S40F
mutant in comparison to P7L (panel D, Western blot
analysis; panel E,VLP release efficiency). That Gag accumu-
lated in aberrant plasma membrane extensions rather than
the characteristic spherical structures under these con-
ditions (i.e., disrupted PTAP motif ) as well as manifest-
ing aberrant egress under conditions when PTAP was
intact suggested that S40 affected a stage in the virusproduction pathway closely linked to budding whether
release was directed by L domain-1 or L domain-2.
The S40F mutation increases Alix binding to Gag in the
yeast 2-hybrid assay
The S40 residue is within the L35YPX2S40L motif that
recruits Alix, but is not an obvious contributor to binding
based on structural studies [29,30]. In contrast, the Y36
residue in the Alix-binding motif contacts Alix [28] and
would therefore be expected to disrupt Gag-Alix inter-
action following substitution of Ser. To confirm this
presumption, we tested the effect of S40 mutations on
Gag-Alix interaction using the well-established yeast
2-hybrid assay. The yeast 2-hybrid assay (Y2H) for protein-
protein interaction has been used in several previous stud-
ies to assess HIV-1 Gag-Alix interaction [11,13,41-43]. In
particular, Lazert et al [43] examined the interaction of full-
length Alix with the p6 minimal region (aa 31–46) that had
been previously implicated in ALIX recognition and found
that introducing Ala at residue 40 was well-tolerated. How-
ever, since Lazert et al also found that the interaction was
modulated by regions outside of the binding site in both p6
and Alix proteins (e.g., the p6 aa 25–28 “hinge” and the Alix
C-terminal Pro-rich domain), we examined the interaction
between full-length Gag and full-length ALIX using a simi-
lar assay. Briefly, in this assay, proteins of interest that are
fused to the DNA-binding (BD) or the activation domain
(AD) of the yeast transcriptional activator, Gal 4, can inter-
act and thereby promote expression of reporter genes [44].
Relative quantification of the protein/protein interaction
strength was monitored by testing for growth on selection
media or by measuring the β-galactosidase activity in yeast
cells co-transformed with the BD- and AD- expressing
plasmids. As shown in Figure 4, panel A, all of the AD-
and BD-chimeric protein pairs tested grew on the double
drop-out selection media (DDO, Trp and Leu), indicating
that the plasmid pairs were expressed. When tested on
the triple drop-out media (TDO, Trp, Leu and His), which
tests for protein-protein interaction, the positive controls
[i.e., full-length Alix paired with P7L-Gag, Tsg101 paired
with WT Gag, and T Ag paired with p53 (lanes 1, 7 or
9; 3 and 5, respectively)] interacted, as expected. The
negative controls (i.e., Tsg101 with P7L, empty vector
paired with empty vector), and P7L-Y36S-Gag paired with
Alix, gave no growth signal also as expected (lanes 2, 4,
and 6, respectively). Co-expression of P7L-S40A and Alix
produced a signal that indicated their interaction (lane 8).
Panel B shows quantification using the beta-galactosidase
reporter. As expected, no signals were obtained for the
negative control samples Tsg101 with P7L or P7L-Y36S
paired with Alix. In contrast, the double mutant, P7L-
S40A-Gag was observed to increase the binding to full-
length Alix an average of 7-fold compared to P7L-Gag.
This result was highly reproducible. In 5 independent
D. C. S40F 



























Figure 2 The budding defect resulting from S40F mutation becomes more apparent when PR is inactive. COS-1 cells were transfected
with plasmids expressing HA-tagged HIV-1 Gag-WT (panels A and B) or Gag-S40F (panels C and D). Cells were prepared for examination by
electron microscopy as described in Methods. Panels A and C, solid arrows, immature particles; open arrows, extended or tethered particles. Bars
in panels A and C measure 500 nm; bars in panel B and D measure 100 nm. The relative frequencies of typical spherical particles and filopodia-like
particles are summarized (panel E).





























































Figure 3 Disrupting L domain-1 increases the effect of the S40F mutation on budding. COS-1 cells were transfected with plasmids
expressing HA-tagged HIV-1 Gag-P7L (panels A1 and A2) or P7L-S40F (panels B1 and B2) and prepared for examination by electron microscopy
as described in Methods. Panels A2, and B2: Samples were labeled with primary rabbit anti-CA antibody that was tagged with 15 nm
gold-conjugated mouse anti-rabbit secondary antibody (bars in panels A1 and A2 measure 100 nm; bars in panels B1 and B2 measure 500 nm).
Panel C, Quantitative analysis of particle morphology. 200 gold-tagged VLPs were counted and the frequency of spherical versus extended
structures were determined (n =2). Panel D, Western Analysis. VLPs and cell lysates from the COS-1 cells transfected with HA-tagged HIV-1
Gag-P7L (lane 1), P7L-S40F (lane 2) were analyzed by Western blotting and gag related proteins identified by monoclonal HA antibody.
Panel E, the relative VLP release efficiencies [VLP/(VLP + Gag from cell lysate)] were determined as described in Methods.
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(p < 0.05). Similar results were obtained for S40F. To
ensure that the enhancing effect of the S40 muta-
tion was directly attributable to Alix binding to the
LYPX2SL motif in the p6 region, the inactivating mu-
tation F676D [28] was introduced into the interacting
V domain of Alix. As shown in panel C, this mutation
reduced Alix binding to WT Gag, P7L-S40A and P7L-
S40F to the level of interaction with the negative con-
trol, Y36S-Gag. We conclude that S40 mutation altered
the binding of full-length Alix to full-length Gag and
that the alteration is directly attributable to the inter-
action between the Alix V domain and the L domain-2
motif in p6.Disrupting Alix interaction with S40F restores spherical
particle formation
As described above, the yeast 2-hybrid assay revealed that
the substitution of F or A for Ser40 in full-length P7L-Gag
increased binding to the full-length Alix compared to the
parental interaction. If the enhanced Alix binding is re-
sponsible for production of the filopodia-like membrane
extensions, then disrupting Alix binding should reduce
formation of the membrane extensions despite the negative
impact on VLP release efficiency due to inhibition of L
domain-2 function. To examine this possibility, we choose
to block Gag-Alix interaction by introducing the Y36S mu-
tation into the Gag-P7L-S40F construct. As described above,
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Figure 4 Gag p6-S40 mutations increase binding to Alix in the yeast 2-hybrid assay. Panel A, Qualitative colony assay. Co-transformed
plasmids encoding protein pairs were tested for interaction under permissive and selective conditions using double drop-out media (DDO, Trp
and Leu) and triple drop-out media (TDO, Trp, Leu, His), respectively. All transformed cells grew on the DDO media, indicating that plasmid pairs
were expressed; only cells expressing interacting pairs grew on the TDO media. Panel B, Quantitative liquid assay. Beta-galactosidase assays were
used to measure the relative strength of the S40 mutants plus Alix interaction. Beta-galactosidase units were normalized to P7L paired with Alix.
Tsg101 plus P7L and Alix plus P7L-Y36S are negative controls. The S40A and S40F results represent five independent clones tested in 5 independ-
ent assays. Panel C, The beta-galactosidase signal is undetectable when the S40 mutants are paired with Alix F676D. WT Gag, P7L-S40A and P7L-S40F
were each paired with wild type Alix or its F676D mutant which does not bind to Gag. Alix paired with Y36S serves as the negative control.
Two independent clones were run in duplicate for each pairing. All values were normalized to WT paired with Alix.
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Examination by immunoelectron microscopy (Figure 5)
showed that formation of the membrane extensions on cells
transfected with DNA encoding P7L-S40F (panels B and E)
was completely suppressed in cells expressing P7L-Y36S-
S40F (panels C and F). Panel C shows that although gold-
tagged P7L-Y36S-S40F accumulated at the cell periphery, the
formation of filopodia-like structures was not induced.Additionally, formation of 100 nm spherical VLPs similar
to those detected in the parental sample (panels A and D)
was restored, althoughVLPs were detected at a much lower
frequency in the P7L-Y36S-S40F sample compared to the
parent. The results indicate that residue S40 plays a key role
in budding and suggest that its effect on Alix binding was
responsible for production of the filopodia-like membrane
extensions containing Gag.
A.  P7L B.  P7L-S40F
2000 nm100 nm 100 nm
D E F
C.  P7L-Y36S-S40F
500 nm 500 nm 100 nm
Figure 5 Disrupting Alix interaction with S40F restores spherical particle formation. COS-1 cells were transfected with plasmids expressing
HA-tagged -P7L (panels A and D), P7L-S40F (panels B and E), or P7L-Y36S-S40F (panels C and F). Panels C-F, cells were prepared for examination
by immunoelectron microscopy as described in Methods. Bars in panels A, and B measure 500 nm; bars in panels C, D and F measure 100 nm; bar in
panel E measures 2000 nm.
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release due to nonfunctional L domains-1 and −2
The budding defects resulting from S40F mutation became
increasingly more pronounced with L domain disruption,
increasing in severity from reduced separation of the
bud from the cell when the S40F mutation was introduced
into L domain-2 (Figure 1B2) to reduced separation of
buds from each other as well as from the cell when the
S40F mutation was combined with L domain-1 disruption
(Figures 2D; 3B2, 5E). Figure 6 shows the effect on budding
when the S40F mutation was combined with disrupting
mutations in both L domain-1 (P7L) and L domain-2
(Y36S) to produce P7L-Y36S-S40F. As noted above, under
these conditions, budding is facilitated by certain isoforms
in the Nedd4 family of ubiquitin E3 ligases working in
conjunction with determinants in the C-terminal domain
(CTD) of the capsid (CA) region in Gag [16,17]. As shown
in lane 3, the introduction of the S40F mutation reduced
virus production compared to the parental P7L-Gag
(lane 1), P7L-Y36S-Gag (lane 2) or P7L-S40F-Gag (lane 4).
Quantitative analysis indicated that VLP release efficiencywas inhibited an average of 10-fold compared to P7L
(n = 7 using 3 independent constructs of P7L-S40F-Gag;
to ensure that this result was due to S40F, the entire
Gag gene was sequenced). Thus, under these conditions,
where both L domain-1 and −2 were disrupted, the bud-
ding defect resulting from the S40F mutation was even
more pronounced, i.e., manifested in a significant block
to viral particle release from cells.
The S40F mutation partially rescues the block to budding
imposed by mutations in the CA NTD
Our studies revealed that the effects of the P7L, Y36S
and P7L-Y36S mutations, which all block budding at a late
stage, were aggravated by the S40F alteration. Interestingly,
residues in the N-terminal domain (NTD) of CA also
contribute to budding since mutation of EE75,76 or
P99 to Ala has been shown to permit Gag accumulation on
the plasma membrane but block the subsequent membrane
evagination, thereby blocking the budding process at an
early stage [13,45,46]. To determine whether the S40F
mutation impacts the phenotype resulting from the CA
AA2. Cell Lysate
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Figure 6 The S40F mutation increases the disruption of virus
release due to nonfunctional L domains-1 and −2. Panel A,
COS-1 cells transfected with DNA encoding the indicated constructs
were analyzed by Western blotting after preparation of VLPs and cell
lysates. Panel B, Quantitative analysis of VLP release efficiency
[VLP/(VLP + Gag from cell lysate)] were determined as described in
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Figure 7 The S40F mutation partially rescues the block to VLP
release efficiency imposed by mutations in the CA NTD. Panel
A, COS-1 cells transfected with DNA encoding the indicated
constructs were analyzed by Western blotting after preparation of
VLPs and cell lysates. Panel B, Quantitative analysis of relative VLP
release efficiency [VLP/(VLP + Gag from cell lysate)] were determined
as described in Methods (n = 3).
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and CA[P99A]-p6[P7L-S40F] and investigated VLP release
efficiency by Western analysis. As shown in Figure 7,
particle production by the parental P7L-Gag construct
(panel A, lane 1) was reduced significantly by introduction
of the CA mutations to form CA [EE75,76AA]-p6[P7L]
(lane 2) and CA[P99A]-p6[P7L] (lane 3). Gag accumulation
within the cell was not significantly affected but VLP
release efficiency was inhibited ~10-fold, n = 3 (panel B).This outcome is expected, based on previous studies
[13,45,46]. In contrast, ~3- to 4- fold more VLPs were
detected in the media of cells expressing the mutants
containing S40F (lanes 5 and 6) as compared to those
lacking it (lanes 2 and 3). As Gag accumulation within
the cell was not similarly increased, the increased VLP
amounts reflected higher VLP release efficiency (panel B).
This indicated that the S40F mutation impacted these
mutants in a positive manner, in contrast to its effect on
the p6 and CA CTD budding determinants. Supporting
this, examination of the CA[EE75,76AA]-p6[P7L-S40F]
(panel E) and the CA[P99A]-p6[P7L-S40F] (panel F) samples










500 nm 500 nm
Figure 8 The S40F mutation suppresses the block to budding imposed by CA[EE75,76AA] and CA[P99A]. The samples described in the
legend to Figure 7 were analyzed by electron microscopy. F. CA[P99A]-p6[P7L-S40F] Panel A, P7L; panel B, CA [EE75,76AA]-p6[P7L]; panel C,
CA[P99A]-p6[P7L]; panel D, P7L-S40F; panel E, CA[EE75,76AA]-p6[P7L-S40F]; and panel F, CA[P99A]-p6[P7L-S40F].
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P7L sample (panel A), albeit at lower frequencies (~10-30%
of parental P7L), as well as elongated particles, similar
to P7L-S40F. In contrast, the CA[EE75,76AA]-p6[P7L]
and CA[P99A]-p6[P7L] samples revealed the expected
dense staining underlying the plasma membrane and no
VLPs (panels B and C). This indicated that the S40F muta-
tion alleviated the defect imposed by the CA mutations, at
least partially. The fact that similar results were obtained
using two different CA mutants that exhibit the membrane
curvature defect strongly suggests that the S40F mutation
can complement their budding defect. Thus, the S40F
mutation appeared to partially rescue the early budding
defect imposed by mutation of the CA NTD determinants
and to aggravate the block to late budding directed by theCA CTD and p6 determinants. These findings implicate
the S40 residue in regulation of an important but previously
unrecognized budding function.
Discussion
Our study identifies a conserved residue in Gag p6
whose mutation had broad impact on budding: The
S40F (and S40A, not shown) mutations (i) interfered
with complete separation of particles from the plasma
membrane in Tsg101-mediated budding; (ii) exacerbated
the block to membrane scission in Alix-mediated budding;
and (iii) inhibited bud release in Nedd4-facilitated egress.
S40 mutation also attenuated the block to membrane
evagination and scission imposed by mutations in the
CA NTD, permitting more efficient VLP release to occur
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http://www.retrovirology.com/content/10/1/143compared to the CA parents. Thus, S40 mutation affected
the budding programs directed by all of the budding
determinants identified to date in HIV-1 Gag. Studies
to date indicate that HIV-1 release is most dependent on
the L domain-1 PTAP-TSG101 Interaction. Nevertheless,
Gag has conserved L domain-2 and determinants in the
CA CTD domain that drive release when both L domain-
1 and-2 are disrupted. The retention and conservation of
these multiple late domains implies that they provide the
virus with an evolutionary advantage, e.g., opportunities
for synergistic interactions between different late domains
in different cell types. The S40 polymorphisms A and F
investigated here were revealed to us in HIV-1 variants
that emerged in infected individuals, consistent with the
notion that the mutations conferred an advantage. In this
case, the advantage could be to virus spread since patients
with these mutations exhibited high virus load and low
CD4 counts that apparently were not controlled by ART or
combo-ART. It was the dominance of variants with these
mutations in the host quasi-species that prompted us to
examine the possibility that the mutations were linked
to the L domain function.
Our findings suggest that S40 is important in the context
of the Gag precursor (in addition to any impact it may have
in the context of the Gag-Pol precursor). An obvious choice
for a Gag assembly function for which S40 is important
involves Gag-Alix interaction as S40 resides within the
L-domain 2 motif that serves as docking site for Alix.
Alix has a modular structure that may permit it to function
in multiple cellular pathways (reviewed in [47-49]). We
found that mutations of S40 to F and A were accom-
panied by novel phenotypes, i.e., greater Alix binding
(in the yeast 2-hybrid assay) and disruption or rescue of
budding determinants. Thus, in combination with other
determinants in Gag besides the ones we tested or other
regions in the genome that can influence the budding
process, a putative S40 regulatory function could provide
multiple opportunities to influence viral budding modes
and release efficiency and thus extend viral fitness.
Both S40F and S40A exhibited increased interaction
with Alix in the yeast 2-hybrid assay and induced the
formation of filopodia-like membrane extensions when
transfected into mammalian cells. This suggested that
the two phenotypes were linked, i.e., that the change in
the Alix-Gag interaction might have resulted in formation
of the unusual budding structures. We provided evidence
to support this hypothesis by demonstrating that disrupting
Alix interaction with the S40F mutant restored spherical
particle formation while suppressing filopodia production.
Residues 1 to 359 of Alix comprise the highly conserved
Bro1 domain that binds the ESCRT-III component Chmp4
[50] and also actin [51]. Residues 360–716 of Alix comprise
a second folded domain, designated as the “V” domain. The
N-terminal “arm” of the V domain binds the actin-bindingprotein, cortactin [51]; the C-terminal “arm” of the domain
binds viral LYPX2S40L [28,29]. Filopodia-like structures
can result when cortactin is recruited by Alix to the cell
periphery and there induces polymerization of cortical
actin through Rho family GTPase signaling [52-56]. As
Alix associates with both cortactin and Gag through the
V domain, it is possible that the enhanced Gag-Alix binding
resulting from the S40F mutation promotes formation
of the filopodia-like structures in regions of the membrane
where L domain-2-mediates VLP formation. Alternatively,
the increased binding of Gag to the Alix V domain might
have affected functions related to the Alix Bro domain,
such as recruitment of CHMP4.
The dramatic effect of S40 mutation on the quality of
the budding event was suppressed by preventing Alix-Gag
interaction, clearly implicating Alix in the S40 function.
Since we observed that S40 mutations altered Gag-Alix
interaction in the yeast 2-hybrid assay, it is possible that
the mutation interfered with Alix binding to its ESCRT or
cytoskeletal protein partners as suggested above. However,
as S40 mutation manifested the greatest impact on viral
particle release efficiency when L domains-1 and −2 were
both disrupted but also resulted in more subtle phenotypes
under less disruptive conditions, we favor the view that
mutation of this residue perturbs a previously unrecognized
budding-related function. As noted above, when L domain-
1 is disrupted, budding is directed by Alix, however, recruit-
ment of a Nedd4 family member is also required [15]. Also
as noted above, when L domain-1 is disrupted, Nedd4
family members can promote release, whether or not L
domain-2 is intact [16,17] and siRNA-mediated depletion
of endogenous Nedd4 prevents release [16]. It seems likely
then that S40 mutation can prevent Nedd4 from con-
tributing to budding directed by L domains −1 and −2.
Conversely, the observation that S40 mutation interfered
with budding mediated by determinants known to direct
release through different cellular factors suggests that
Nedd4 contributes to HIV budding even in conditions
where its involvement has not yet been established, i.e.,
when directed by L domain-1 or CA NTD determinants.
HIV-1 Gag lacks the conventional PY motif that is known
to recognize Nedd4. However, we observed that its binding
partner Tsg101 can associate with some family members
[57] and also that Tsg101 can functionally replace Nedd4
function is some aspects of Avian Sarcoma Virus (ASV)
Gag release [27]. Moreover, the motif in which S40 resides
in Gag p6, LYPLXS40L is very similar to that found in
another Alix binding partner, the membrane-associated
protein MD 9/syntenin (LYPSL; [58,59]). In the case of
syntenin, the motif, along with multimerization deter-
minants in the protein, are essential for its interaction
with ubiquitin. Also possibly pertinent to our findings,
the overexpression of syntenin was observed to enhance
formation of filopodia, linking its unusual interaction with
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the Ser residue in the motif is subject to phosphorylation
and its modification regulates the interaction of syntenin
with ubiquitin. These results define an unprecedented
ubiquitin-dependent pathway regulated by a kinase. By
analogy, the S40 residue in Gag p6 could become phos-
phorylated and serve as a platform for Nedd4-mediated
ubiquitin modifications involved in budding. In this event,
the substitution of any amino acid except possibly Thr
would be expected to have deleterious effects. It has
recently been suggested that the p6 region modulates the
membrane interactions of HIV-1 Gag and that phosphor-
ylation of S40 amplifies that interaction significantly [60].
It will be of interest to determine which of the afore-
mentioned mechanisms underlies the impact of S40
mutation on L domain function observed in our study.
In any case, the identification of a novel p6 role in viral
assembly and budding may provide new targets and/or
strategies for design of anti-viral agents.
Conclusions
The substitution of Phe for a conserved residue in Gag
p6, S40, can differentially affect L domain function.
Our findings suggest that residue S40 is a determinant




Plasmids pHIV-1-gag-HA tagged with hemagglutinin (HA)
[61], pNL4-3ΔEnv [62] and pIIIB-Env3-1 [63] have been
previously described. Yeast plasmid pGAD containing the
full-length Alix (pGAD-Alix) was a generous gift from
Dr. F. Bouamr (NIH). Yeast plasmid pGBT9 containing
Gag was constructed by subcloning codon-optimized
Gag [64]. Mutations in Gag and Alix were constructed by
site-directed mutagenesis (Agilent). Gag-related proteins
were detected using a polyclonal antibody against the
native form of the capsid protein [65] or by a mouse
monoclonal (Sigma-Aldrich) to the HA tag. Actin levels
were detected by using a monoclonal antibody against
actin (Sigma-Aldrich).
Viral particle infectivity
COS1 cells were co-transfected with pNL4-3ΔEnv
(wild type or constructs) and pIIIB env3-1 plasmids. At
48 h post-transfection, the culture medium was passed
through a 0.45um pore size filter to separate virus from
cells. The concentration of p24 in the filtered medium
was determined by ELISA (Immunodiagnostics, Inc.) and
equivalent amounts of p24 were used to infect MAGI cells
[39]. Efficiency of infectivity at 48 hrs was measured as de-
scribed [66]. As a control to verify that equivalent amounts
of Env was expressed in each transfection, virus preps wererun on SDS-PAGE followed by Western blot analysis using
anti-HIV envelope antibodies (Immunodiagnostics, Inc.).
Yeast 2-hybrid assays
HIV-1 Gag wild-type and mutants were tested for protein-
protein interactions using the Matchmaker GAL4 Yeast
Two Hybrid system (Clontech) with Saccharomyces
cerevisiae strains AH109 (selective media assay) and Y190
(beta-galactosidase assay) as instructed by the manufacturer.
Transfection and western blots
COS-1 cells were cultured in Dulbecco’s modified Eagle’s
medium supplemented with fetal bovine serum (5%)
and antibiotics (1%) to approximately 60% confluency
at 37°C. The cells were transfected using XtremeGene
reagent (Roche). At 48 h post-transfection, the culture
medium was separated from the cells and the cells were
washed in PBS and lysed in buffer (50 mM Tris, pH 7.4,
137 mM NaCl, 1.5 mM MgCl2, 1 mM EDTA, 1% Triton
X-100, 10% glycerol) containing protease inhibitors (Roche).
Virus particles were passed through a 0.45um pore size
filter and isolated by ultracentrifugation through a cushion
of 20% sucrose at 36,000 rpm for 90 min at 4°C using a
Beckman SW41 rotor. Proteins were separated on 10 or
12% SDS polyacrylamide gels and identified by Western
blotting. Proteins were visualized using an infrared-based
imaging system (Odyssey, LI-COR Biotechnology). The
secondary antibodies used to detect protein expression
were Alexa Fluor 680 goat anti-mouse IgG (Molecular
Probes, 1:10,000) and IRDyeTM800-conjugated affinity
purified goat anti-rabbit IgG (Rockland, 1:10,000). For
analysis of virus-like particle (VLP) release efficiency,
measurements of bands corresponding to Gag in VLPs
and cell lysates were made using the Li-Cor Odyssey
software version 2.1.15. Release efficiency was defined as the
ratio of the signal intensity value for the VLP-associated Gag
to the sum of the values for VLP-associated Gag plus cell
lysate-associated Gag [VLP/(VLP +Gag from cell lysate)].
Electron microscopy
Cells grown on ACLAR film were fixed in 4% paraformal-
dehyde/0.1% EM grade glutaraldehyde in PBS, soaked in
2% osmium tetroxide, dehydrated in a graded series of ethyl
alcohol solutions and embedded in Durpan resin. Eighty
nm ultrathin sections were counterstained with uranyl
acetate and lead citrate and viewed with a FEI Tecanal
BioTwinG2 electron microscope. Immunogold labeling
was as described in Ehrlich et al [67].
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